The biotech IPO window, at the start of the year at least, was wide open, leaving more than a few people scratching their heads when eye disease biotech Gyroscope Therapeutics said back in May it was ditching its plans because of “market conditions.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,